KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Change in Cash (2018 - 2025)

ClearPoint Neuro's Change in Cash history spans 13 years, with the latest figure at -$3.3 million for Q3 2025.

  • For Q3 2025, Change in Cash rose 70.55% year-over-year to -$3.3 million; the TTM value through Sep 2025 reached $16.8 million, up 707.73%, while the annual FY2024 figure was -$3.0 million, 32.16% up from the prior year.
  • Change in Cash for Q3 2025 was -$3.3 million at ClearPoint Neuro, down from $29.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $44.8 million in Q1 2021 and bottomed at -$26.1 million in Q2 2022.
  • The 5-year median for Change in Cash is -$3.3 million (2025), against an average of $963263.2.
  • The largest annual shift saw Change in Cash plummeted 683.86% in 2022 before it skyrocketed 1269.62% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$3.5 million in 2021, then skyrocketed by 351.36% to $8.9 million in 2022, then tumbled by 113.5% to -$1.2 million in 2023, then dropped by 22.21% to -$1.5 million in 2024, then tumbled by 126.0% to -$3.3 million in 2025.
  • Per Business Quant, the three most recent readings for CLPT's Change in Cash are -$3.3 million (Q3 2025), $29.3 million (Q2 2025), and -$7.7 million (Q1 2025).